Akoya Biosciences Inc (NAS:AKYA)
$ 2.8 0.03 (1.08%) Market Cap: 137.11 Mil Enterprise Value: 176.59 Mil PE Ratio: 0 PB Ratio: 6.16 GF Score: 40/100

Akoya Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 14, 2022 / 12:35PM GMT
Release Date Price: $12.77 (+1.03%)
Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

Good morning, everyone. Thanks for joining us. My name is Tejas Savant, I'm the life science tools and diagnostics analyst at Morgan Stanley. It's my pleasure this morning to host Akoya, and from the company, we have Brian, Niro and Joe. So thanks, gentlemen, for doing this. Appreciate it. Before we kick it off, quickly need to rattle off the disclosures here, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, do reach out to your sales rep. So with that, Brian, thanks again. Before we get into the meat and bones of the discussion, can you just take a couple of minutes to just briefly recap the story where Akoya fits into the spatial biology landscape? And what are you most proud of over the last 12 months?

Brian McKelligon
Akoya Biosciences, Inc. - President, CEO & Director

Great. Well, thanks again for having us. We really do appreciate it. maybe just to pull back a little bit. It's pretty -- it's been really

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot